Asia Pacific Antibody Drug Conjugates Market
市场规模（十亿美元）
CAGR :
% 
USD
1.77 Billion
USD
6.11 Billion
2023
2031
 Forecast Period |
2024 –2031 |
 Market Size (Base Year) |
USD 1.77 Billion |
 Market Size (Forecast Year) |
USD 6.11 Billion |
 CAGR |
% |
| Major Markets Players |
>亚太抗体药物偶联物 (ADC) 市场细分，按产品（Enhertu、Kadcyla、Trodelvy、Polivy、Adcetris、Padcev、Besponsa、Elahere、Zylonta、Mylotarg、Tivdak 等）、抗原成分（HER2 受体、Trop-2、CD79B、CD30、Nectin 4、CD22、CD19、CD33、组织因子等）、抗体成分（第三代 ADC、第二代 ADC、第四代 ADC 和第一代 ADC）、接头成分（可裂解接头和不可裂解接头）、细胞毒性有效载荷或弹头成分（DNA 损伤剂和微管破坏剂）、接头技术（肽接头、硫醚接头、腙接头和二硫键接头）、偶联技术（位点特异性结合和化学结合）、适应症（乳腺癌、血癌（白血病、淋巴瘤）、肺癌、妇科癌症、胃肠道癌症、泌尿生殖系统癌症等）、最终用户（医院、专科中心、诊所、门诊中心、家庭医疗保健等）、分销渠道（直接招标、零售销售等） - 行业趋势和预测至 2031 年
抗体药物偶联物 (ADC) 市场分析
2024年5月，根据美国国家癌症研究所公布的数据，预计2024年美国将新增200万癌症病例，死亡人数为611,720人。主要癌症包括乳腺癌、前列腺癌、肺癌、结直肠癌和黑色素瘤。前列腺癌、肺癌和结直肠癌占男性病例的48%，乳腺癌、肺癌和结直肠癌占女性病例的51%。年发病率为每10万人440.5人，死亡率为每10万人146.0人。在儿童和青少年（0-19岁）中，预计将有14,910人被诊断出癌症，其中1,590人死亡。FDA批准的ADC数量不断增加，临床试验也越来越多，凸显了市场的潜力。然而，制造成本高、生产过程复杂等挑战可能会影响增长。总体而言，在技术进步和肿瘤治疗日益普及的支持下，北美 ADC 市场有望实现长足发展。
抗体药物偶联物 (ADC) 市场规模
2023 年亚太抗体药物偶联物 (ADC) 市场规模价值 17.7 亿美元，预计到 2031 年将达到 61.1 亿美元，2024 年至 2031 年预测期内的复合年增长率为 16.7%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括进出口分析、生产能力概览、生产消费分析、价格趋势分析、气候变化情景、供应链分析、价值链分析、原材料/消耗品概览、供应商选择标准、PESTLE 分析、波特分析和监管框架。
抗体药物偶联物 (ADC) 市场趋势
“抗体-药物偶联物 (ADC) 技术的进展”
抗体-药物偶联物 (ADC) 技术的进步通过提高癌症治疗的疗效和安全性，推动了亚太地区 ADC 市场的增长。关键创新趋势包括改进的连接体，以实现稳定、精确的药物输送，以癌细胞为目标，同时保护健康组织。具有优化有效载荷和生物标志物驱动的患者选择的下一代 ADC 可确保治疗惠及最受益者，最大限度地减少副作用。此外，改进的制造工艺正在降低生产成本、增加可及性并鼓励加大对 ADC 开发的投资，所有这些都有助于建立强大的产品线并扩大市场兴趣。
报告范围和抗体药物偶联物 (ADC) 市场细分
|
属性 |
抗体药物偶联物 (ADC) 关键市场洞察 |
|
涵盖的领域 |
|
|
覆盖国家 |
日本、中国、印度、澳大利亚、新加坡和亚太地区其他地区 |
|
主要市场参与者 |
第一三共株式会社（日本）、罗氏制药有限公司（瑞士）、吉利德科学公司（美国）、安斯泰来制药公司（日本）、武田制药公司（日本）、辉瑞公司（美国）、艾伯维公司（美国）、ADC Therapeutics（瑞士）、安进公司（加利福尼亚州）、阿斯利康公司（英国）、拜耳公司（德国）、Byondis（荷兰）、卫材公司（日本）、葛兰素史克公司（英国）、强生服务公司（美国）、Oxford BioTherapeutics（英国）、Remegen（中国）、赛诺菲（法国）和 Sutra Biopharma 公司（美国） |
|
市场机会 |
|
|
增值数据信息集 |
除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解之外，Data Bridge Market Research 策划的市场报告还包括进出口分析、生产能力概览、生产消费分析、价格趋势分析、气候变化情景、供应链分析、价值链分析、原材料/消耗品概览、供应商选择标准、PESTLE 分析、波特分析和监管框架。 |
抗体药物偶联物 (ADC) 市场定义
抗体-药物偶联物 (ADC) 是一种靶向癌症疗法，将抗体与强效抗癌药物相结合。抗体特异性地与癌细胞标记物结合，将药物直接递送至癌细胞，同时最大限度地减少对健康细胞的影响。这种精准性减少了副作用并提高了药物治疗癌症的有效性。
抗体药物偶联物 (ADC) 市场动态
驱动程序
- 癌症发病率不断上升
癌症发病率的上升极大地推动了北美抗体药物偶联物 (ADC) 市场的发展，增加了对有针对性、有效治疗的需求。ADC 通过将单克隆抗体与强效细胞毒性药物相结合，提供精确的癌细胞靶向性，同时减少对健康组织的伤害。随着癌症发病率的上升，制药公司正在大力投资 ADC 技术，以满足对更个性化治疗的需求，尤其是针对具有挑战性的癌症类型。癌症患者人数的增长加速了 ADC 临床试验、监管部门的批准和商业发布，进一步推动了 ADC 市场的发展。
例如，
2024 年 2 月，根据世界卫生组织发表的一篇文章，2022 年估计有 2000 万例新发癌症病例和 970 万人死亡，5350 万人在诊断后五年内存活。肺癌是最常见的癌症（250 万例，12.4%），其次是乳腺癌（230 万例，11.6%）、结直肠癌（190 万例，9.6%）、前列腺癌（150 万例，7.3%）和胃癌（97 万例，4.9%）。五分之一的人会患上癌症，预计到 2050 年新发病例将超过 3500 万例，增长 77%。发病率的上升推动了靶向癌症治疗市场的增长。
癌症发病率的上升显著促进了北美 ADC 市场的发展，增加了对有针对性、有效疗法的需求。ADC 能够直接向癌细胞提供有效的治疗，同时保护健康组织，因此作为一种有前途的解决方案而受到关注。日益增长的癌症负担推动了 ADC 技术的研究、开发和投资，推动了新的进步并扩大了市场
- 抗体-药物偶联物 (ADC) 技术的进展
抗体-药物偶联物 (ADC) 技术的进步通过提高癌症治疗的疗效和安全性，推动了全球 ADC 市场的增长。关键创新包括改进的连接体，以实现稳定、精确的药物输送，以癌细胞为目标，同时保护健康组织。具有优化有效载荷和生物标志物驱动的患者选择的下一代 ADC 可确保疗法惠及最受益者，最大限度地减少副作用。此外，改进的制造工艺降低了生产成本，增加了可及性，并鼓励加大对 ADC 开发的投资，所有这些都有助于建立强大的产品线并扩大市场兴趣。
例如，
2023 年 10 月，根据《中国药学学报 B》发表的文章，ADC 研究的最新进展侧重于开发更安全、更有效的载荷。关键进展包括更强的细胞毒性药物、用于精确递送的稳定连接体以及 DNA 损伤剂和免疫调节剂等新型载荷。这些创新扩大了治疗窗口，降低了脱靶毒性并提高了对抗耐药肿瘤的有效性，塑造了下一代 ADC。
增强型连接系统和有效药物有效载荷等创新提高了癌症治疗的精确度和安全性。生物标志物引导策略增强了患者靶向性，以实现最佳疗效。改进的制造技术使 ADC 更易于获取且更具成本效益，从而吸引了投资并扩大了治疗选择。总体而言，这些进步提高了 ADC 的有效性，并刺激了市场增长和制药行业的兴趣
机会
抗体药物偶联物 (ADCS) 肿瘤学研发管线不断壮大
抗体药物偶联物 (ADC) 的肿瘤学产品线正在迅速扩大，具有巨大的市场潜力。受肿瘤生物学进展和靶向治疗需求的推动，许多 ADC 候选药物正处于不同的开发阶段。
制药和生物技术公司正在大力投资新型 ADC，以提高对一系列癌症（包括实体瘤和血液系统恶性肿瘤）的疗效和安全性。连接技术、有效载荷和抗体工程方面的创新正在带来更有效、毒性更低的 ADC，拓宽治疗选择并吸引投资者的兴趣。
例如，
2024 年 8 月，根据强生创新有限责任公司发表的文章，强生公司不断增长的抗体药物偶联物 (ADC) 疗法产品线和积极的合作表明了其对 ADC 领域的坚定承诺。他们对创新、安全和有效的癌症治疗的重视展示了 ADC 的变革潜力。这些举措促进了行业伙伴关系，增强了开发和可及性，并在北美 ADC 市场创造了巨大的增长机会。
- 增加对癌症研究的投资
增加对癌症研究的投资为全球抗体药物偶联物 (ADC) 市场的增长提供了重大机遇。随着政府、私人组织和慈善机构优先考虑有效的癌症治疗，这些资金对于推进创新的 ADC 疗法至关重要。
这些投资使研究人员能够加深对肿瘤生物学和药物作用机制的了解，这对于开发更有针对性和更有效的 ADC 至关重要。此外，增加的资金有助于开展更大规模和更多样化的临床试验，提高对患者反应的了解，并加快有前途的 ADC 候选药物的评估和审批流程。
例如，
2024 年 10 月，根据 UKRI 发表的文章，Innovate UK 和 OLS 将在先进精准医疗竞赛的六个项目中投资 519 万美元，这是生命科学愿景癌症任务的一部分。这笔巨额资金凸显了对癌症研究和开发的日益重视。此类投资为包括抗体-药物偶联物 (ADC) 在内的创新疗法铺平了道路，为全球 ADC 市场的增长创造了宝贵的机会。
限制/挑战
- 开发成本高且制造复杂
研究需要大量投资，包括创新接头设计、选择细胞毒性药物和优化结合技术，这大大增加了成本。复杂的制造过程需要精确的药物抗体连接和严格的质量控制，这进一步推高了费用。此外，安全高效生产所需的专业设施和设备增加了财务负担，使小型生物技术公司难以进行 ADC 开发，而大型公司则一次只能进行几个项目。因此，虽然 ADC 提供了有希望的靶向癌症疗法，但这些问题限制了市场增长和新疗法的引入。
例如，
2024年7月，根据《抗体药物偶联物杂志》发表的文章，百时美施贵宝（BMS）预付8亿美元，获得Systimmune的EGFR x HER3双特异性ADC BL-B01D1（Zalontamab brengitecan）的许可，该药物目前在美国处于1期，在中国处于3期。虽然BL-B01D1在经过大量治疗的转移性实体瘤中显示出良好的安全性和有效性，但高昂的投资成本令人担忧。此外，开发双特异性ADC也存在挑战，例如选择合适的抗体形式，这通常需要创建两个稳定的细胞系。这种复杂性增加了制造成本并使检测开发复杂化
高昂的开发成本和制造复杂性严重阻碍了北美抗体-药物偶联物 (ADC) 市场的增长。研究所需的大量资金投入和复杂的制造工艺导致生产费用增加。这种复杂性不仅需要严格的质量控制措施，还需要专门的设施和设备，这进一步加剧了资源紧张。因此，较小的生物技术公司可能不愿意进入市场，而较大的公司可能会限制其 ADC 计划。
- 抗体药物偶联物的安全性和毒性问题
安全性和毒性问题是全球抗体药物偶联物 (ADC) 市场增长的主要制约因素。尽管 ADC 的设计目标是针对癌细胞，但由于其强大的细胞毒性，ADC 可能会对健康组织产生不利影响，导致全身毒性和副作用，如中性粒细胞减少症和器官特异性毒性。此外，不可预测的免疫反应可能导致过敏反应或免疫原性，从而限制其在某些患者群体中的使用。脱靶效应的风险（即 ADC 影响具有类似抗原的非癌细胞）使治疗更加复杂。
例如，
2021 年 6 月，根据爱思唯尔发布的新闻稿，脱靶毒性是抗体-药物偶联物 (ADC) 剂量限制性副作用的主要原因，主要是由于连接物-药物不稳定和过早有效载荷释放。这种狭窄的治疗指数需要在临床前和临床阶段进行彻底的安全评估。改进测试方法和了解安全性对于优化 ADC 的治疗潜力至关重要。
安全性和毒性问题是全球 ADC 市场面临的主要挑战，因为强效细胞毒性药物可能导致严重的副作用，包括血液疾病和器官特异性毒性。免疫反应和脱靶效应的风险使其安全使用变得复杂，需要严格的临床测试和监管监督。
抗体药物偶联物 (ADC) 市场范围
市场根据产品、抗原成分、抗体成分、连接体成分、细胞毒性有效载荷或弹头成分、连接体技术、结合技术、适应症、最终用户和分销渠道进行细分。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。
产品
- 恩赫尔图
- 卡德西拉
- 波代尔维
- 艾德西特利斯
- 帕德切夫
- 贝斯蓬萨
- 埃拉希尔
- 泽洛塔
- 麦罗塔格
- 蒂夫达克
- 其他的
抗原成分
- HER2 受体
- 促红细胞生成素-2
- CD79B
- CD30
- 连接蛋白4
- CD22 型
- CD19
- CD33
- 组织因素
- 其他的
抗体成分
- 第三代 ADC
- 第二代 ADC
- 第四代 ADC
- 第一代 ADC
链接器组件
- 可裂解接头
- 肽基
- 酸敏感或酸不稳定
- 谷胱甘肽敏感二硫化物
- 不可裂解接头
细胞毒性有效载荷或弹头部件
- DNA损伤剂
- 喜树碱
- 加利车霉素
- 吡咯并苯二氮卓类
- 微管破坏剂
- 奥瑞他汀
- 美登素类
联创科技
- 肽连接子
- 硫醚连接基
- 腙连接子
- 二硫键连接子
共轭技术
- 位点特异性结合
- 化学共轭
指征
- 乳腺癌
- 血癌（白血病、淋巴瘤）
- 肺癌
- 妇科癌症
- 胃肠道癌症
- 泌尿生殖系统癌症
- 其他的
最终用户
- 医院
- 专业中心
- 诊所
- 门诊中心
- 家庭医疗保健
- 其他的
分销渠道
- 直接招标
- 零售
- 医院药房
- 零售药店
- 网上药店
- 其他的
抗体药物偶联物 (ADC) 市场区域分析
对市场进行分析，并按国家、产品、抗原成分、抗体成分、连接体成分、细胞毒性有效载荷或弹头成分、连接体技术、结合技术、适应症、最终用户和分销渠道提供市场规模洞察和趋势，如上所述。
市场覆盖的国家包括日本、中国、印度、澳大利亚、新加坡和亚太其他地区。
日本凭借其先进的医疗保健基础设施、对创新医疗设备的高需求以及对质量和患者护理的高度重视，有望在市场中占据主导地位。
由于先进医疗技术的采用日益广泛、慢性病患病率不断上升以及对具有成本效益的长期血管通路解决方案的日益重视，日本预计将成为增长最快的国家。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化影响了市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了亚太品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
抗体药物偶联物 (ADC) 市场份额
市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、亚太地区业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对市场的关注有关。
抗体药物偶联物 (ADC) 市场领导者有：
- 第一三共株式会社（日本）
- F. Hoffmann-La Roche Ltd (基因泰克) (瑞士)
- 吉利德科学公司（美国）
- 安斯泰来制药有限公司 (日本)
- 武田（日本）
- 辉瑞公司 (美国)
- Abbvie（美国）
- ADC Therapeutics（瑞士）
- 安进公司（美国）
- 阿斯利康（英国）
- 拜耳（德国）
- Byondis（荷兰）
- 卫材株式会社 (日本)
- 葛兰素史克公司 (英国)
- 强生服务公司（美国）
- 牛津大治疗公司（英国）
- 雷美吉（中国）
- 赛诺菲（法国）
- Sutra Biopharma（美国）
抗体药物偶联物 (ADC) 市场的最新发展
- 2024 年 10 月，第一三共和阿斯利康的 ENHERTU 在中国获得有条件批准，成为首个针对 HER2 突变转移性非小细胞肺癌 (NSCLC) 成人患者的 HER2 靶向疗法。该批准基于 DESTINY-Lung02 和 DESTINY-Lung05 研究的积极结果，凸显了 ENHERTU 对既往接受过治疗的患者具有疗效。这标志着 ENHERTU 在中国针对各种肿瘤类型的第四个适应症，增强了两家公司的肿瘤学产品组合，并解决了肺癌治疗领域未得到满足的重大需求
- 2024 年 8 月，拜耳与 NextRNA Therapeutics 宣布达成合作与许可协议，以开发针对肿瘤学中长链非编码 RNA (lncRNA) 的小分子疗法，为破坏疾病治疗中的 lncRNA-RBP 相互作用提供一种新方法
- 2023 年 3 月，罗氏宣布与礼来合作开发 Elecsys 淀粉样血浆检测板。这项创新的血液检测旨在促进阿尔茨海默病的早期诊断，解决重大障碍并改善患者及时接受治疗的机会
- 2022 年 1 月，罗氏推出了创新型手持式血糖管理设备 cobas pulse 系统。该系统将先进的数字功能与用户友好的设计相结合，简化了医护人员的工作流程，并增强了各种环境下的患者护理
- 2024 年 6 月，武田扩大了与健康伙伴组织 (PIH) 的合作，以改善马萨诸塞州的健康公平。该计划将建立健康公平实践社区，增强地方卫生部门的能力，并为社区卫生工作者创造更多机会
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 PESTEL ANALYSIS
5 COST STRUCTURE ANALYSIS OF ANTIBODY-DRUG CONJUGATE (ADC) MANUFACTURING
5.1 ANTIBODIES
5.1.1 OVERVIEW OF ANTIBODY PRODUCTION
5.1.1.1 In-house vs. Outsourced:
5.1.2 ANTIBODY PRICING FACTORS
5.2 LINKERS
5.2.1 ROLE AND TYPES OF LINKERS
5.2.1.1 Cost Impact by Linker Type:
5.3 CYTOTOXIC AGENTS
5.3.1 COST CONSIDERATIONS:
5.3.2 BUFFERS AND SOLVENTS
5.4 COST BREAKDOWN BY MANUFACTURING STAGE
5.4.1 PRE-PRODUCTION COSTS
5.4.2 CONJUGATION PROCESS
5.4.3 PURIFICATION AND FILTRATION
5.4.4 QUALITY CONTROL
5.5 COST PROJECTIONS AND PRICING TRENDS (2024–2030)
5.5.1 PROJECTED COST FLUCTUATIONS
5.5.2 COST IMPACT OF SCALABILITY
5.6 SUPPLIER AND GEOGRAPHIC PRICING TRENDS
5.6.1 GEOGRAPHIC COST VARIATIONS
5.6.2 SUPPLIER ANALYSIS
5.6.3 CONCLUSION
6 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE OF CANCER
7.1.2 ADVANCES IN ANTIBODY-DRUG CONJUGATE (ADC) TECHNOLOGY
7.1.3 INCREASING DEMAND FOR TARGETED THERAPIES
7.1.4 ADVANCEMENTS IN PROTEOMICS AND GENOMICS RESEARCH
7.2 RESTRAINTS
7.2.1 HIGH DEVELOPMENT COST & MANUFACTURING COMPLEXITIES
7.2.2 SAFETY AND TOXICITY ISSUES OF ANTIBODY DRUG CONJUGATES
7.3 OPPORTUNITIES
7.3.1 GROWING ONCOLOGY PIPELINE FOR ANTIBODY DRUG CONJUGATES (ADCS)
7.3.2 INCREASING INVESTMENT IN CANCER RESEARCH
7.3.3 INCREASING COLLABORATION WITH RESEARCH INSTITUTIONS FOR ANTIBODY DRUG CONJUGATES
7.4 CHALLENGES
7.4.1 CLINICAL TRIAL FAILURES FOR ANTIBODY DRUG CONJUGATES DEVELOPMENT
7.4.2 LENGTHY CLINICAL TRIALS AND DEVELOPMENT PHASES
8 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT
8.1 OVERVIEW
8.2 ENHERTU
8.3 KADCYLA
8.4 TRODELVY
8.5 POLIVY
8.6 ADCETRIS
8.7 PADCEV
8.8 BESPONSA
8.9 ELAHERE
8.1 ZYLONTA
8.11 MYLOTARG
8.12 TIVDAK
8.13 OTHERS
9 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT
9.1 OVERVIEW
9.2 HER2 RECEPTOR
9.3 TROP-2
9.4 CD79B
9.5 CD30
9.6 NECTIN 4
9.7 CD22
9.8 CD19
9.9 CD33
9.1 TISSUE FACTORS
9.11 OTHERS
10 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT
10.1 OVERVIEW
10.2 THIRD GENERATION ADCS
10.3 SECOND GENERATION ADCS
10.4 FOURTH GENERATION ADCS
10.5 FIRST GENERATION ADCS
11 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT
11.1 OVERVIEW
11.2 CLEAVABLE LINKERS
11.2.1 PEPTIDE BASED
11.2.2 ACID SENSITIVE OR ACID LABILE
11.2.3 GLUTATHIONE SENSITIVE DISULFIDE
11.3 NON CLEAVABLE LINKERS
12 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT
12.1 OVERVIEW
12.2 DNA DAMAGING AGENTS
12.2.1 CAMPTOTHECIN
12.2.2 CALICHEAMICIN
12.2.3 PYRROLOBENZODIAZEPINES
12.3 MICROTUBULE DISRUPTING AGENTS
12.3.1 AURISTATIN
12.3.2 MAYTANSINOIDS
13 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY
13.1 OVERVIEW
13.2 PEPTIDE LINKERS
13.3 THIOETHER LINKERS
13.4 HYDRAZONE LINKERS
13.5 DISULFIDE LINKERS
14 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY
14.1 OVERVIEW
14.2 SITE-SPECIFIC CONJUGATION
14.3 CHEMICAL CONJUGATION
15 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION
15.1 OVERVIEW
15.2 BREAST CANCER
15.3 BLOOD CANCER (LEUKEMIA, LYMPHOMA)
15.4 LUNG CANCER
15.5 GYNECOLOGICAL CANCER
15.6 GASTROINTESTINAL CANCER
15.7 GENITOURINARY CANCER
15.8 OTHERS
16 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER
16.1 OVERVIEW
16.2 HOSPITALS
16.3 SPECIALTY CENTER
16.4 CLINICS
16.5 AMBULATORY CENTERS
16.6 HOME HEALTHCARE
16.7 OTHERS
17 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 DIRECT TENDERS
17.3 RETAIL SALES
17.3.1 HOSPITAL PHARMACY
17.3.2 RETAIL PHARMACY
17.3.3 ONLINE PHARMACY
17.4 OTHERS
18 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION
18.1 ASIA-PACIFIC
18.1.1 JAPAN
18.1.2 CHINA
18.1.3 INDIA
18.1.4 AUSTRALIA
18.1.5 SINGAPORE
18.1.6 REST OF ASIA-PACIFIC
19 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC): COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: GLOBAL
20 SWOT ANALYSIS
21 COMPANY PROFILES
21.1 DAIICHI SANKYO, INC.
21.1.1 COMPANY SNAPSHOT
21.1.2 REVENUE ANALYSIS
21.1.3 PRODUCT PORTFOLIO
21.1.4 RECENT DEVELOPMENT
21.2 F. HOFFMANN-LA ROCHE LTD
21.2.1 COMPANY SNAPSHOT
21.2.2 REVENUE ANALYSIS
21.2.3 PRODUCT PORTFOLIO
21.2.4 RECENT DEVELOPMENT
21.3 GILEAD SCIENCES, INC.
21.3.1 COMPANY SNAPSHOT
21.3.2 REVENUE
21.3.3 PRODUCT PORTFOLIO
21.3.4 RECENT DEVELOPMENT
21.4 ASTELLAS PHARMA INC.
21.4.1 COMPANY SNAPSHOT
21.4.2 REVENUE ANALYSIS
21.4.3 PRODUCT PORTFOLIO
21.4.4 RECENT DEVELOPMENT
21.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED
21.5.1 COMPANY SNAPSHOT
21.5.2 REVENUE ANALYSIS
21.5.3 PRODUCT PORTFOLIO
21.5.4 RECENT DEVELOPMENT
21.6 ABBVIE INC.
21.6.1 COMPANY SNAPSHOT
21.6.2 REVENUE
21.6.3 PRODUCT PORTFOLIO
21.6.4 RECENT DEVELOPMENT
21.7 ADC THERAPEUTICS SA
21.7.1 6.1 COMPANY SNAPSHOT
21.7.2 REVENUE ANALYSIS
21.7.3 PRODUCT PORTFOLIO
21.7.4 RECENT DEVELOPMENT
21.8 AMGEN, INC.
21.8.1 COMPANY SNAPSHOT
21.8.2 REVENUE ANALYSIS
21.8.3 PRODUCT PORTFOLIO
21.8.4 RECENT DEVELOPMENT
21.9 ASTRAZENECA
21.9.1 COMPANY SNAPSHOT
21.9.2 REVENUE ANALYSIS
21.9.3 PRODUCT PORTFOLIO
21.9.4 RECENT DEVELOPMENT
21.1 BAYER
21.10.1 COMPANY SNAPSHOT
21.10.2 REVENUE ANALYSIS
21.10.3 PRODUCT PORTFOLIO
21.10.4 RECENT DEVELOPMENT
21.11 BYONDIS
21.11.1 COMPANY SNAPSHOT
21.11.2 PRODUCT PORTFOLIO
21.11.3 RECENT DEVELOPMENT
21.12 EISAI INC
21.12.1 COMPANY SNAPSHOT
21.12.2 REVENUE ANALYSIS
21.12.3 PRODUCT PORTFOLIO
21.12.4 RECENT DEVELOPMENT
21.13 GSK PLC
21.13.1 COMPANY SNAPSHOT
21.13.2 REVENUE ANALYSIS
21.13.3 PRODUCT PORTFOLIO
21.13.4 RECENT DEVELOPMENT
21.14 JOHNSON & JOHNSON SERVICES, INC.
21.14.1 COMPANY SNAPSHOT
21.14.2 REVENUE ANALYSIS
21.14.3 PRODUCT PORTFOLIO
21.14.4 RECENT DEVELOPMENT
21.15 OXFORD BIOTHERAPEUTICS
21.15.1 COMPANY SNAPSHOT
21.15.2 PRODUCT PORTFOLIO
21.15.3 RECENT DEVELOPMENT
21.16 PFIZER INC.
21.16.1 COMPANY SNAPSHOT
21.16.2 REVENUE ANALYSIS
21.16.3 PRODUCT PORTFOLIO
21.16.4 RECENT UPDATES
21.17 REMEGEN
21.17.1 COMPANY SNAPSHOT
21.17.2 PRODUCT PORTFOLIO
21.17.3 RECENT DEVELOPMENTS
21.18 SANOFI
21.18.1 COMPANY SNAPSHOT
21.18.2 REVENUE ANALYSIS
21.18.3 PRODUCT PORTFOLIO
21.18.4 RECENT DEVELOPMENT
21.19 SUTRO BIOPHARMA, INC.
21.19.1 COMPANY SNAPSHOT
21.19.2 REVENUE ANALYSIS
21.19.3 PRODUCT PORTFOLIO
21.19.4 RECENT UPDATES
22 QUESTIONNAIRE
23 RELATED REPORTS
表格列表
TABLE 1 PROJECTED PRICE CHANGE (2024–2030)
TABLE 2 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 3 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 4 ASIA-PACIFIC ENHERTU IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 5 ASIA-PACIFIC KADCYLA IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 6 ASIA-PACIFIC TRODELVY IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 7 ASIA-PACIFIC POLIVY IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 8 ASIA-PACIFIC ADCETRIS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 9 ASIA-PACIFIC PADCEV IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 10 ASIA-PACIFIC BESPONSA IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 11 ASIA-PACIFIC ELAHERE IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 12 ASIA-PACIFIC ZYLONTA IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 13 ASIA-PACIFIC MYLOTARG IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 14 ASIA-PACIFIC TIVDAK IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 15 ASIA-PACIFIC OTHERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 16 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)
TABLE 17 ASIA-PACIFIC HER2 RECEPTOR IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 18 ASIA-PACIFIC TROP-2 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 19 ASIA-PACIFIC CD79B IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 20 ASIA-PACIFIC CD30 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 21 ASIA-PACIFIC NECTIN 4 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 22 ASIA-PACIFIC CD22 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 23 ASIA-PACIFIC CD19 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 24 ASIA-PACIFIC CD33 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 25 ASIA-PACIFIC TISSUE FACTORS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 26 ASIA-PACIFIC OTHERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 27 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)
TABLE 28 ASIA-PACIFIC THIRD GENERATION ADCS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 29 ASIA-PACIFIC SECOND GENERATION ADCS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 30 ASIA-PACIFIC FOURTH GENERATION ADCS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 31 ASIA-PACIFIC FIRST GENERATION ADCS IN OPHTHALMOLOGY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 32 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)
TABLE 33 ASIA-PACIFIC CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 34 ASIA-PACIFIC CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 35 ASIA-PACIFIC NON CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 36 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 37 ASIA-PACIFIC DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 38 ASIA-PACIFIC DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 39 ASIA-PACIFIC MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 40 ASIA-PACIFIC MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 41 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 42 ASIA-PACIFIC PEPTIDE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 43 ASIA-PACIFIC THIOETHER LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 44 ASIA-PACIFIC HYDRAZONE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 45 ASIA-PACIFIC DISULFIDE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 46 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 47 ASIA-PACIFIC SITE-SPECIFIC CONJUGATION IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 48 ASIA-PACIFIC CHEMICAL CONJUGATION IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 49 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 50 ASIA-PACIFIC BREAST CANCER IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 51 ASIA-PACIFIC BLOOD CANCER (LEUKEMIA, LYMPHOMA) IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 52 ASIA-PACIFIC LUNG CANCER IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 53 ASIA-PACIFIC GYNECOLOGICAL CANCER IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 54 ASIA-PACIFIC GASTROINTESTINAL CANCER IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 55 ASIA-PACIFIC GENITOURINARY CANCER IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 56 ASIA-PACIFIC OTHERS IN OPHTHALMOLOGY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 57 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 58 ASIA-PACIFIC HOSPITALS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 59 ASIA-PACIFIC SPECIALTY CENTERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 60 ASIA-PACIFIC CLINICS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 61 ASIA-PACIFIC AMBULATORY CENTERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 62 ASIA-PACIFIC HOME HEALTHCARE IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 63 ASIA-PACIFIC OTHERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 64 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 65 ASIA-PACIFIC DIRECT TENDERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 66 ASIA-PACIFIC RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 67 ASIA-PACIFIC RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 68 ASIA-PACIFIC OTHERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 69 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 70 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 71 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 72 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)
TABLE 73 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)
TABLE 74 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)
TABLE 75 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)
TABLE 76 ASIA-PACIFIC CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 77 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 78 ASIA-PACIFIC DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 79 ASIA-PACIFIC MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 80 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 81 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 82 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 83 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 84 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 85 ASIA-PACIFIC RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 86 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 87 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 88 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)
TABLE 89 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)
TABLE 90 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)
TABLE 91 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)
TABLE 92 JAPAN CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 93 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 94 JAPAN DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 95 JAPAN MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 96 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 97 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 98 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 99 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 100 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 101 JAPAN RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 102 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 103 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 104 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)
TABLE 105 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)
TABLE 106 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)
TABLE 107 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)
TABLE 108 CHINA CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 109 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 110 CHINA DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 111 CHINA MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 112 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 113 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 114 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 115 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 116 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 117 CHINA RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 118 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 119 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 120 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)
TABLE 121 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)
TABLE 122 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)
TABLE 123 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)
TABLE 124 INDIA CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 125 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 126 INDIA DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 127 INDIA MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 128 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 129 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 130 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 131 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 132 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 133 INDIA RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 134 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 135 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 136 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)
TABLE 137 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)
TABLE 138 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)
TABLE 139 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)
TABLE 140 AUSTRALIA CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 141 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 142 AUSTRALIA DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 143 AUSTRALIA MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 144 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 145 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 146 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 147 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 148 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 149 AUSTRALIA RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 150 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 151 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 152 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)
TABLE 153 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)
TABLE 154 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)
TABLE 155 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)
TABLE 156 SINGAPORE CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 157 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 158 SINGAPORE DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 159 SINGAPORE MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 160 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 161 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 162 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 163 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 164 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 165 SINGAPORE RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 166 REST OF ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 167 REST OF ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 168 REST OF ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)
图片列表
FIGURE 1 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: SEGMENTATION
FIGURE 11 EXECUTIVE SUMMARY
FIGURE 12 STRATEGIC DECISIONS
FIGURE 13 RISING INCIDENCE OF CANCER IS DRIVING THE GROWTH OF THE ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET FROM 2024 TO 2031
FIGURE 14 THE PRODUCT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET IN 2024 AND 2031
FIGURE 15 DROC
FIGURE 16 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY PRODUCT, 2023
FIGURE 17 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY PRODUCT, 2024-2031 (USD MILLION)
FIGURE 18 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY PRODUCT, CAGR (2024-2031)
FIGURE 19 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 20 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIGEN COMPONENT, 2023
FIGURE 21 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIGEN COMPONENT, 2024-2031 (USD MILLION)
FIGURE 22 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIGEN COMPONENT, CAGR (2024-2031)
FIGURE 23 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIGEN COMPONENT, LIFELINE CURVE
FIGURE 24 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIBODY COMPONENT, 2023
FIGURE 25 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIBODY COMPONENT, 2024-2031 (USD MILLION)
FIGURE 26 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIBODY COMPONENT, CAGR (2024-2031)
FIGURE 27 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIBODY COMPONENT, LIFELINE CURVE
FIGURE 28 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKERS COMPONENT, 2023
FIGURE 29 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKERS COMPONENT, 2024-2031 (USD MILLION)
FIGURE 30 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKERS COMPONENT, CAGR (2024-2031)
FIGURE 31 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKERS COMPONENT, LIFELINE CURVE
FIGURE 32 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2023
FIGURE 33 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2024-2031 (USD MILLION)
FIGURE 34 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, CAGR (2024-2031)
FIGURE 35 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, LIFELINE CURVE
FIGURE 36 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKER TECHNOLOGY, 2023
FIGURE 37 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKER TECHNOLOGY, 2024-2031 (USD MILLION)
FIGURE 38 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKER TECHNOLOGY, CAGR (2024-2031)
FIGURE 39 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKER TECHNOLOGY, LIFELINE CURVE
FIGURE 40 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CONJUGATION TECHNOLOGY, 2023
FIGURE 41 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CONJUGATION TECHNOLOGY, 2024-2031 (USD MILLION)
FIGURE 42 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CONJUGATION TECHNOLOGY, CAGR (2024-2031)
FIGURE 43 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CONJUGATION TECHNOLOGY, LIFELINE CURVE
FIGURE 44 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY INDICATION, 2023
FIGURE 45 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY INDICATION, 2024-2031 (USD MILLION)
FIGURE 46 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY INDICATION, CAGR (2024-2031)
FIGURE 47 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 48 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY END USER, 2023
FIGURE 49 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 50 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY END USER, CAGR (2024-2031)
FIGURE 51 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY END USER, LIFELINE CURVE
FIGURE 52 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 53 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 54 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 55 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 56 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: SNAPSHOT (2023)
FIGURE 57 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC): COMPANY SHARE 2023 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
